Our portfolio companies are here to help.

 
 

Fund 2 Companies

 
  Chrono is combining a biologically timed transdermal drug delivery system with a behavorial support delivered via an app to help people manage hard-to-treat conditions. Their first application is smoking cessation.

 

Chrono is combining a biologically timed transdermal drug delivery system with a behavorial support delivered via an app to help people manage hard-to-treat conditions. Their first application is smoking cessation.

  Using a proprietary collagen-based technology, Innocoll is successfully distributing products that treat post-operative pain, heal diabetic foot infections, and prevent post-surgical adhesions. Innocoll is listed on the NASDAQ as INNL.

 

Using a proprietary collagen-based technology, Innocoll is successfully distributing products that treat post-operative pain, heal diabetic foot infections, and prevent post-surgical adhesions. Innocoll is listed on the NASDAQ as INNL.

  Using neuromodulation treatments, Neuromod is helping people with chronic and often debilitating tinnitus, informally called "ringing in the ears."

 

Using neuromodulation treatments, Neuromod is helping people with chronic and often debilitating tinnitus, informally called "ringing in the ears."

  Inflammasomes generate signals that cause immune cells to fight infections. Inflazome is developing novel treatments for inflammation-related diseases by precisely blocking unwanted inflammasome signals.

 

Inflammasomes generate signals that cause immune cells to fight infections. Inflazome is developing novel treatments for inflammation-related diseases by precisely blocking unwanted inflammasome signals.

 
Developing a unique portfolio of neurokinin (NK) receptor antagonists, NeRRe Therapeutics is aiming to treat common debilitating respiratory and women's health conditions caused by neuronal hypersensitivity.

Developing a unique portfolio of neurokinin (NK) receptor antagonists, NeRRe Therapeutics is aiming to treat common debilitating respiratory and women's health conditions caused by neuronal hypersensitivity.

 
 

Fund 1 Companies

 
  With extensive experience in lipid science, Amarin is developing novel therapeutics for the treatment of cardiovascular disorders. Fountain has exited this investment.

 

With extensive experience in lipid science, Amarin is developing novel therapeutics for the treatment of cardiovascular disorders. Fountain has exited this investment.

  Before being acquired by Acorda Therapeutics for $525M in cash in October 2014, Civitas was applying its dry powder inhalation drug delivery technology to Parkinson’s treatments. Fountain has exited this investment.

 

Before being acquired by Acorda Therapeutics for $525M in cash in October 2014, Civitas was applying its dry powder inhalation drug delivery technology to Parkinson’s treatments. Fountain has exited this investment.

  Targeting the human immune system, Opsona is developing drugs with wide applicability to conditions such as autoimmune and inflammatory diseases, solid organ transplantation and oncology.

 

Targeting the human immune system, Opsona is developing drugs with wide applicability to conditions such as autoimmune and inflammatory diseases, solid organ transplantation and oncology.

  Leveraging oral small molecules, Trino Therapeutics is focused on treating and managing inflammatory indications such as inflammatory bowel disease (IBD).

 

Leveraging oral small molecules, Trino Therapeutics is focused on treating and managing inflammatory indications such as inflammatory bowel disease (IBD).

  Genable developed a gene therapy platform to suppress and replace genes associated with Retinitis Pigmentosa. The company was acquired by Spark Therapeutics in March 2016. Fountain has exited this investment.

 

Genable developed a gene therapy platform to suppress and replace genes associated with Retinitis Pigmentosa. The company was acquired by Spark Therapeutics in March 2016. Fountain has exited this investment.

  Following a successful IPO, Mainstay Medical is bringing to market an implantable neurostimulation system for people with disabling Chronic Low Back Pain (CLBP).

 

Following a successful IPO, Mainstay Medical is bringing to market an implantable neurostimulation system for people with disabling Chronic Low Back Pain (CLBP).

  With their unique interventional neurovascular device, now commercially available, Neuravi is improving clinical outcomes for stroke patients.

 

With their unique interventional neurovascular device, now commercially available, Neuravi is improving clinical outcomes for stroke patients.

  Aiming to help people undergoing vascular surgery, Vivasure Medical has developed a bioabsorbable technology delivered percutaneously to assist in vessel closure.

 

Aiming to help people undergoing vascular surgery, Vivasure Medical has developed a bioabsorbable technology delivered percutaneously to assist in vessel closure.

  Cappella built and distributed a bifurcation stent to protect coronary sidebranch arteries during cardiac procedures. Now called ArraVasc Limited, they are focused on peripheral vascular products. This investment is inactive.

 

Cappella built and distributed a bifurcation stent to protect coronary sidebranch arteries during cardiac procedures. Now called ArraVasc Limited, they are focused on peripheral vascular products. This investment is inactive.

  With an implantable infusion pump, Palyon Medical was treating chronic pain, spasticity and diseases of the central nervous system. The company ceased operations in 2015 and this investment is inactive.

 

With an implantable infusion pump, Palyon Medical was treating chronic pain, spasticity and diseases of the central nervous system. The company ceased operations in 2015 and this investment is inactive.